Goldman Sachs Resumes Seattle Genetics (SGEN) at Neutral
Tweet
Share
E-mailGet Alerts SGEN Hot Sheet
Price: $228.74 --0%
Rating Summary:
10 Buy, 18 Hold, 5 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
10 Buy, 18 Hold, 5 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Goldman Sachs resumes coverage on Seattle Genetics (NASDAQ: SGEN) with a Neutral rating and $20 price target.
The firm views the company as a high quality story, with the first targeted drug to treat niche blood cancers. However, they believe the current valuation reflects Adcetris's initial opportunity.
For more ratings news on Seattle Genetics click here and for the rating history of Seattle Genetics click here.
Shares of Seattle Genetics closed at $19.04 yesterday.
The firm views the company as a high quality story, with the first targeted drug to treat niche blood cancers. However, they believe the current valuation reflects Adcetris's initial opportunity.
For more ratings news on Seattle Genetics click here and for the rating history of Seattle Genetics click here.
Shares of Seattle Genetics closed at $19.04 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham Starts Faeth Therapeutics (FTH) at Buy
- BofA Securities Starts Mobility Global (MBGL) at Neutral
- BMO Capital Starts Broadcom Limited (AVGO) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
